🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 26/06/2013 | 78,77 | 81,32 | 78,02 | 80,32 | +2,84% | 4,19% | 1.495.100 |
| 25/06/2013 | 77,34 | 78,91 | 77,08 | 78,10 | +1,87% | 2,37% | 1.070.800 |
| 24/06/2013 | 75,03 | 77,18 | 73,40 | 76,67 | +0,91% | 5,04% | 1.495.200 |
| 21/06/2013 | 75,89 | 76,87 | 74,20 | 75,98 | -0,24% | 3,52% | 4.288.600 |
| 20/06/2013 | 76,80 | 77,73 | 75,30 | 76,16 | -2,20% | 3,16% | 1.877.200 |
| 19/06/2013 | 79,07 | 80,42 | 77,85 | 77,87 | -1,18% | 3,25% | 1.685.200 |
| 18/06/2013 | 79,08 | 79,59 | 77,45 | 78,80 | +0,06% | 2,71% | 1.967.900 |
| 17/06/2013 | 81,22 | 81,50 | 77,56 | 78,75 | -1,94% | 4,85% | 1.821.400 |
| 14/06/2013 | 82,32 | 82,85 | 79,91 | 80,31 | -2,84% | 3,57% | 1.456.300 |
| 13/06/2013 | 82,25 | 84,62 | 78,79 | 82,66 | +3,03% | 7,09% | 1.945.900 |
| 12/06/2013 | 82,08 | 83,02 | 79,79 | 80,23 | -1,44% | 3,94% | 928.200 |
| 11/06/2013 | 81,92 | 84,84 | 81,09 | 81,40 | -2,09% | 4,58% | 1.616.700 |
| 10/06/2013 | 82,66 | 83,17 | 80,71 | 83,14 | +0,40% | 2,98% | 1.511.400 |
| 07/06/2013 | 77,99 | 84,72 | 77,97 | 82,81 | +6,14% | 8,65% | 3.126.500 |
| 06/06/2013 | 77,30 | 79,15 | 77,10 | 78,02 | +1,39% | 2,65% | 1.564.200 |
| 05/06/2013 | 78,38 | 79,45 | 76,16 | 76,95 | -1,80% | 4,20% | 1.737.300 |
| 04/06/2013 | 78,77 | 80,18 | 78,03 | 78,36 | -1,22% | 2,73% | 1.041.000 |
| 03/06/2013 | 80,83 | 81,00 | 77,46 | 79,33 | -1,24% | 4,38% | 1.492.300 |
| 31/05/2013 | 82,18 | 82,97 | 80,11 | 80,33 | -3,38% | 3,48% | 1.747.700 |
| 30/05/2013 | 78,43 | 83,94 | 78,26 | 83,14 | +6,06% | 7,24% | 2.422.800 |
| 29/05/2013 | 77,46 | 78,96 | 76,97 | 78,39 | +0,47% | 2,57% | 1.094.400 |
| 28/05/2013 | 79,28 | 79,61 | 76,94 | 78,02 | -0,48% | 3,37% | 1.432.900 |
| 24/05/2013 | 77,50 | 78,46 | 76,73 | 78,40 | -0,10% | 2,23% | 859.300 |
| 23/05/2013 | 78,19 | 79,47 | 77,16 | 78,48 | +0,06% | 2,95% | 1.663.600 |
| 22/05/2013 | 79,40 | 81,45 | 77,67 | 78,43 | -1,31% | 4,76% | 1.446.100 |
| 21/05/2013 | 77,61 | 79,87 | 77,49 | 79,47 | +2,70% | 3,07% | 1.722.400 |
| 20/05/2013 | 79,03 | 79,57 | 77,08 | 77,38 | -2,65% | 3,15% | 2.072.800 |
| 17/05/2013 | 78,72 | 79,54 | 77,69 | 79,49 | +2,05% | 2,35% | 2.622.700 |
| 16/05/2013 | 78,67 | 79,31 | 75,85 | 77,89 | -1,93% | 4,40% | 2.475.200 |
| 15/05/2013 | 80,20 | 81,00 | 78,38 | 79,42 | -1,96% | 3,27% | 1.644.600 |